This inventor holds 1 USPTO granted patent. Top assignee: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Li Sheng - Innovator in Pharmaceutical Development
Introduction
Li Sheng is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of active pharmaceutical ingredients. His innovative work has led to the creation of a unique compound that addresses specific impurities in pharmaceutical formulations.
Latest Patents
Li Sheng holds a patent for the "Nemonoxacin malate active pharmaceutical ingredient with low combination impurities, and a preparation method thereof." This patent outlines a method for preparing the nemonoxacin malate active pharmaceutical ingredient, which includes the use of a C1-C3 alcohol/water mixed solvent to dissolve nemonoxacin free base and D,L-malic acid. The process involves cooling crystallization, followed by solid-liquid separation, washing, and drying to obtain the final product.
Career Highlights
Li Sheng is associated with Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory, where he has played a crucial role in pharmaceutical research and development. His expertise in the field has been instrumental in advancing the company's product offerings and enhancing the quality of pharmaceutical ingredients.
Collaborations
Li Sheng has collaborated with notable colleagues, including Gang Fan and Dadong Shen. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical sector.
Conclusion
Li Sheng's contributions to pharmaceutical innovation, particularly through his patented work, highlight his role as a key figure in the industry. His dedication to improving pharmaceutical formulations continues to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile